FGF4 Overexpression

CI-VAR-00417093Explore in graph →CIViC 5582

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
FGF4 Overexpression	Sorafenib	Predictive	D	Supports Sensitivity Response	3	submitted	EID13277 In A549 xenografts engineered to stably overexpress FGF4 protein, oral sorafenib at 15 mg/kg/day significantly inhibited tumor growth relative to vehicle treatment, whereas the same low-dose regimen w… (full text at CIViC) PMID 22890726 · Arao et al., 2013 · Open in CIViC	civic
Unmapped disease1unmapped disease
FGF4 Overexpression	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID13278 A549 cells engineered to overexpress FGF4 protein formed xenografts that increased in volume more aggressively than control A549/EGFP tumors, indicating that increased FGF4 protein expression enhanced… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.